AJANTPHARM vs MANKIND: Stock Comparison

Ajanta Pharma Limited vs Mankind Pharma Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Mankind Pharma Limited is the larger company by market capitalisation. Ajanta Pharma Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Ajanta Pharma Limited and Mankind Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, AJANTPHARM is more favourable on 10 of 13 scored metrics and MANKIND on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
MANKIND is the larger company
₹1.08 L Cr vs ₹41,751 Cr
P/E Ratio
AJANTPHARM has a lower P/E
39.47x vs 56.71x
P/B Ratio
MANKIND has a lower P/B
6.66x vs 9.21x
EPS
AJANTPHARM has higher earnings per share
₹84.57 vs ₹46.34
Dividend Yield
AJANTPHARM has a higher dividend yield
1.66% vs 0.04%
Revenue Growth (TTM YoY)
AJANTPHARM has faster revenue growth
21.5% vs 11.8%
EPS Growth (TTM YoY)
MANKIND has faster EPS growth
31.7% vs 18.6%
Qtr Sales Growth
AJANTPHARM has stronger quarterly sales growth
21.5% vs 11.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAJANTPHARMMANKIND
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAJANTPHARMMANKIND
Live Price₹3,342.4₹2,617.9
Day Change-1.29%2.6%
Volume76,5976.1 L
52-Week High₹3,598.8₹2,674
52-Week Low₹2,329.9₹1,909.7
Distance from 52W High-7.12%-2.1%

Valuation

MetricAJANTPHARMMANKIND
Market Cap₹41,751 Cr₹1.08 L Cr
P/E Ratio39.47x56.71x
P/B Ratio9.21x6.66x
EPS₹84.57₹46.34
Book Value₹362.41₹395.2
Dividend Yield1.66%0.04%

Growth

MetricAJANTPHARMMANKIND
Revenue Growth (TTM YoY)21.5%11.8%
EPS Growth (TTM YoY)18.6%31.7%
Qtr Sales Growth21.5%11.8%
Qtr Profit Growth18.4%34.2%

Profitability & Leverage

MetricAJANTPHARMMANKIND
ROE27.1%13.1%
ROCE34.5%13.5%
Net Margin19.38%13.34%
Operating Margin27.5%25.3%
Debt to Equity0.06x0.39x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAJANTPHARMMANKIND
Promoter Holding63.48% 2.77 pp72.63% 0.03 pp
FII Holding7.68% 0.58 pp9.45% 0.79 pp
DII Holding21.8% 3.43 pp15.39% 0.93 pp
Public Holding7.03% 0.09 pp2.53% 0.11 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Ajanta Pharma Limited and Mankind Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.